February is ADAPTABLE’s time to shine.
The groundbreaking pragmatic clinical trial coordinated by the Duke Clinical Research Institute, ADAPTABLE is comparing the effectiveness of two different daily doses of aspirin widely used to prevent heart attacks and strokes in individuals living with heart disease. The study is funded through a PCORI grant and is the first demonstration project being conducted by PCORnet.
The study is embracing a new paradigm of patient engagement in clinical research. The ADAPTABLE patient partners, Adaptors, work alongside researchers in all aspects of the trial, including designing the protocol, consent form, study portal, and study materials, to ensure that the patient voice is incorporated into the study.
ADAPTABLE celebrated February’s Heart Month via its unique partnerships and patient engagement channels, most notably Facebook and its patient partners. The team held its second Facebook Live event and also participated in a national art project that celebrates clinical trial participants. Both were fantastic opportunities to engage with the community and spread awareness of the unique and innovative elements of ADAPTABLE.
Facebook Live Event
On February 13 the study team hosted its second Facebook Live event, broadcast live from Duke. DCRI’s Matthew Roe, MD, MHS, ADAPTABLE Co-Principal Investigator, moderated the event and was joined by DCRI’s Schuyler Jones and Daniel Munoz, MD, MPA from Vanderbilt University Medical Center. Clifton Walker, an ADAPTABLE participant who has heart disease and who is followed in the Duke Cardiology Clinic by Dr. Roe, shared his journey with heart disease and why he believes ADAPTABLE is important to finding the right dose of aspirin.
The event’s objective was to raise awareness of ADAPTABLE and how it is transforming clinical research with unique patient partnerships and innovative enrollment, recruitment, and retention strategies. Watch the video in case you missed the live event.
The team promoted the event to the ADAPTABLE community and beyond using a “social media kit” approach. The kit contained suggested tweets, Facebook posts, and images for organizations, networks, sites, and individuals to easily share on their channels. Immediately after the event, the video had 1.6K views. At the time of this article, the video has had more than 4.5K views with a reach of more than 20K people.
These Facebook Live events, coupled with active Facebook and Twitter accounts for the ADAPTABLE trial, provide a robust and innovative way to connect with patients, clinicians, and the broader community and serve as a model for future patient-centered studies.
Hero’s Journey Art Piece
To showcase the tremendous patient engagement in ADAPTABLE, in January and February the study team coordinated participation in the Hero’s Journey art project. Sponsored by Eli Lilly, the national art project involves more than 1,000 participants and is intended to honor clinical trial participants and raise awareness of clinical trials.
ADAPTABLE’s patient partners, in conjunction with Health eHeart Alliance, crafted the quote “Better health outcomes for all when patients partner with researchers” to represent their involvement in clinical research.
The brick will become part of an eight-foot tall, egg-shaped, lighted sculpture (see photo below) that will tour the U.S. before Eli Lilly installs them permanently.
“ADAPTABLE is a best-in-class example of how the DCRI is at the leading edge of trials that incorporate meaningful patient engagement,” said Holly Robertson, PhD, ADAPTABLE project lead. “It’s exciting to be a part of a study that is transforming clinical research.”
Partnerships to Improve Clinical Research
In addition to using social media to reach patients, the study team is developing collaborations with the American Heart Association (AHA) and American College of Cardiology (ACC) to generate study awareness and education among patients with heart disease and the healthcare providers that treat them.
“ADAPTABLE has unique collaborations with patients, clinicians, health systems, and professional associations in a way that has never been done before on such a large scale in cardiovascular research,” said Co-Principal Investigator Matthew Roe, MD, MHS. “ADAPTABLE is truly a signature study in how collaborations can improve the conduct of clinical research.”
AHA will continue to feature ADAPTABLE through their social media channels and support future Facebook Live events. At the March ACC Scientific Sessions, the ADAPTABLE team will host a panel discussion in the Patient Engagement Pavilion. Two ADAPTORS, Henry Cruz and Tom McCormick, will be on the panel, joined by Drs. Robert Califf, Eileen Handberg, Sandeep Jain, and Fred Masoudi. Dr. Roe will moderate. The panelists will focus on informing conference attendees about the benefits of patient-centered research and how partnering with patients can lead to better research questions and protocols, and ultimately better outcomes for all.